Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255744 | 1.00 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL5453883 | 0.86 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1892201 | 0.81 | CSNK1D (0.65) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6077523 | 0.81 | CSNK1D (0.65) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL5462121 | 0.81 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL2929529 | 0.79 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6028249 | 0.79 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL16105552 | 0.77 | CSNK1D (0.53) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1386983 | 0.77 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL12570357 | 0.77 | CSNK1D (0.63) | MAPK14MAPK13MAPK12MAPK11CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019005-B2 | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2006-03-28 | — | — | US | claimed |
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | claimed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | claimed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | claimed |
| CN-1264376-A | 3(5)-Heteroaryl substituted pyrazoles as P38 kinase inhibitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | claimed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | claimed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-7019005-B2 | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-6579873-B2 | Treatment of inflammation, arthritis, bone disorders, respiratory system disorders | PHARMACIA CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | disclosed |
| CN-1264376-A | 3(5)-Heteroaryl substituted pyrazoles as P38 kinase inhibitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | disclosed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 26/4885MAPK13 28/4885MAPK12 50/4885 |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 26/4885MAPK13 28/4885MAPK12 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.